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Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint synovial inflammation, as well as cartilage and bone
tissue destruction. Current strategies for the treatment of RA can reduce joint inflammation, but the treatment options still represent
stability concerns since they are not sufficient and present a fast clearing. Thus, several drug delivery systems (DDS) have been
advanced to tackle this limitation. Injectable gellan gum (GG) hydrogels, reduced by physical crosslinking methods, also being
proposed as DDS, but this kind of crosslinking can produce hydrogels that become weaker in physiological conditions.
Nevertheless, enzymatic crosslinking emerged as an alternative to increase mechanical strength, which can be adjusted by the degree
of enzymatic crosslinking. In this study, tyramine-modified gellan gum (Ty-GG) hydrogels were developed via horseradish peroxidase
(HRP) crosslinking; and betamethasone was encapsulated within, to increase the specificity and safety in the treatment of patients with
RA. Physicochemical results showed that it was possible to modify GG with tyramine, with a degree of substitution of approximately
30%. They showed high mechanical strength and resistance, presenting a controlled betamethasone release profile over time. Ty-GG
hydrogels also exhibited no cytotoxic effects and do not negatively affected the metabolic activity and proliferation of chondrogenic
primary cells. Furthermore, the main goal was achieved since betamethasone-loaded Ty-GG hydrogels demonstrated to have a more
effective therapeutic effect when compared with the administration of betamethasone alone. Therefore, the developed Ty-GG
hydrogels represent a promising DDS and a reliable alternative to traditional treatments in patients with RA.
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Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease,
with a complex pathology that affects about 1% of the
worldwide population [1, 2]. It is characterized by progressive
chronic inflammation of joints and the proliferation of the
synovium leading to pannus formation, bones, and cartilage
destruction. It is associated with persistent arthritic pain,
swelling, stiffness, and work disability. RA is also responsible
for the decreased expectancy and quality of life, being more
prevalent in women than men [3, 4].
Despite the recent advances in medical therapeutics, cur-
rently, it is only possible to slow down the progression of the
disease and attempt to increase the quality of life, being not
possible to cure RA. The most commonly used therapeutic
agents for RA include disease-modifying anti-rheumatic
drugs, glucocorticoids, non-steroidal anti-inflammatory drugs,
and biological agents. However, such therapies have several
drawbacks due to quite a few side effects, such as headaches,
dizziness, insomnia, damage to the skin and hair, cytopenia,
and transaminase elevation, among others, mainly caused by
the lack of selectivity of the drugs and also frequent and long-
term dosing that lead to patient non-compliance [5, 6].
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A possible solution to avoid the undesired side effects is the
drug delivery directly to the affected site, via intra-articular
injection.
Compared with traditional methods currently used for the
administration of drugs, the use of biomaterials as drug deliv-
ery systems present many advantages. Those advantages are
related, for instance, with the improvement of the insoluble
drug delivery, maximizing the bioavailability, and the treat-
ment efficacy. Furthermore, the use of biomaterials can help to
reduce secondary effects and enhance the plasma half-life of
peptide drugs by protecting them from degradation caused by
the environment [7, 8].
Hydrogels are three-dimensional, crosslinked networks of
water-soluble polymers that have physiochemical similarities
to the extracellular matrix, namely, mechanical and composi-
tion properties. The particular physical properties of hydrogels
have encouraged the interest in their use in drug delivery ap-
plications. The porosity of the hydrogels also enables the
charging of drugs into the gel matrix and posterior controlled
drug release [9, 10].
An injectable hydrogel is a class of hydrogel, which can
convert from solution to gel in situ upon physical or chemical
stimuli. Therefore, these hydrogels can be introduced into a
defined position of the body through a minimally invasive
method [11, 12].
Gellan gum (GG) is a bacterial polysaccharide obtained
from Sphingomonas elodea, and its glycosidic backbone is a
repeating tetrasaccharide unit with one L-glycerate per repeat-
ing unit and one acetate, occurring every two sequences as
esterified substituents [13]. GG is biodegradable, biocompat-
ible, and non-toxic. In tissue engineering, the versatility of this
polysaccharide has been studied to develop drug delivery sys-
tems such as the development of injectable hydrogels [14].
Physical crosslinkingmethods can produce GG hydrogels that
become weaker in physiological conditions since a switch of
divalent cations by monovalent ones and physically
crosslinked hydrogels occur, leading to the loss of in vivo
stability after implantation [15, 16]. Enzymatically
crosslinked hydrogels, including covalent bonds between the
polymer chains, are produced via radical polymerization and
non-enzymatic or enzymatic crosslinking of complementary
groups [17, 18]. Enzyme-mediated hydrogel formation is a
suitable method of crosslinking materials in the aqueous me-
dium due to the reaction condition desirable near physiologi-
cal pH and room temperature. Furthermore, enzymatic
hydrogelation prevent the production of undesirable by-
products or cytotoxic composite because enzymes only work
with distinct substrates [19, 20].
Enzymatic crosslinking of polymer-phenol conjugates
in the presence of horseradish peroxidase (HRP) and
H2O2 has emerged as a valuable method to synthesize in
situ forming (injectable hydrogels) due to fast gelation
and control lable cross l inking densi ty [21, 22] .
Furthermore, HRP has moderate substrate specificity and
can easily be a tuned hydrogel network by adjusting the
concentration of enzyme and subtract [19, 23]. Several
research groups reported the in situ formation of
hydrogels through the functionalization of polymers with
tyramine. The hydrogels are chemically crosslinked and
consequently possess superior characteristics in terms of
stability and mechanical resistance when compared with
physically crosslinked and been widely used in drug de-
livery [24].
In this work, it was developed tyramine-modified gellan
gum (Ty-GG) hydrogels (crosslinked by both physical and
chemical mechanisms) in the presence of horseradish peroxi-
dase (HRP) and hydrogen peroxide (H2O2). The Ty-GG
hydrogels were loadedwith betamethasone in order to provide
its sustain release and improve the treatment safety in patients
with RA. Physicochemical characterization was performed to
evaluate the successful functionalization of Ty-GG using nu-
clear magnetic resonance (1H-NMR) and Fourier-transform
infrared (FTIR) spectroscopic techniques. Furthermore, the
betamethasone-loaded Ty-GG hydrogel water uptake, weight
loss, gelation time, injectability, and rheological properties
were assessed. The betamethasone release profile from the
Ty-GG hydrogels was also evaluated in vitro. In vitro studies
for cell viability such as 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide and DNA proliferation on
chondrogenic primary cells and anti-inflammatory activity by
enzyme-linked immunosorbent in THP-1 cell line were
performed.
Materials and methods
Synthesis of tyramine-gellan gum
The functionalization of gellan gum with tyramine was
carried out following the method reported by Prodanovic
et al. [25], with minor changes. Briefly, gellan gum from
Gelzan™ CM (Sigma-Aldrich, USA) was dissolved in
water at 90 °C to a final concentration of 1% (w/v).
Sodium (meta)periodate (Sigma-Aldrich, USA) was added
to a final concentration of 1 mM in GG at 1% (w/v). The
reaction was kept in the dark for 24 h at 4 °C. The reac-
tion was then stopped by adding glycerol (500 mM) and
incubated for 30 min in the dark at 4 °C. The oxidized
GG was precipitated from the reaction mixture by adding
NaCl at 1% (w/v) and 2 volumes of 99% (v/v) ethanol.
This precipitation step was repeated two times, using the
same procedure after dissolving oxidized GG at 1% (w/v)
concentration in water. In the end, the precipitate was
separated, dried, and dissolved in 0.1 M sodium-
phosphate buffer pH 6. When dissolved at 1% (w/v) con-
centration, tyramine hydrochloride (Sigma-Aldrich, USA)
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was added by molecular equivalents (number of mol
equivalents of GG to number of mol equivalents of tyra-
mine), and the solution was stirred for 30 min.
Subsequently, solid cyanoborohydride was added at
0.5% (w/v) final concentration, and the reaction mixture
was left in the dark for 24 h at 4 °C. Modified gellan gum
was precipitated by adding NaCl to 1 M final concentra-
tion and two volumes of 96% (v/v) ethanol. Precipitation
was repeated two times using the same procedure after
dissolving modified GG at 1% (w/v) concentration in wa-
ter. Ty-GG powder was obtained by lyophilization, at
0.08 mbar and − 77.7 °C, during approximately 4 days.
Physicochemical characterization
Fourier-transform infrared spectroscopy
Powder samples of Ty-GG, GG, and tyramine were mixed
with potassium bromide, and, using a manual press, a
transparent pellet was obtained. The transmission spectra
of the samples were obtained on an IR Prestige-21 spec-
trometer (Shimadzu, Japan), using 32 scans, a resolution
of 4 cm−1, and a wavenumber range between 4400 and
400 cm−1.
Assessment of the degree of substitution of tyramine
in gellan gum
The chemical modification of GG with Ty was evaluated
and quantified by proton nuclear magnetic resonance
spectroscopy (1H-NMR). Ty-GG was solubilized in deu-
terium water oxide (D2O) (2 mg mL
−1) at room tempera-
ture. Then, 1 mL of the sample was transferred to an
NMR tube. The NMR spectra were obtained on a
Bruker AVANCE 400 spectrometer, at 50 °C using a res-
onance frequency of 400 MHz. To process and analyze
the obtained spectra, MestReNova 9.0 Software was used.
The degree of substitution (DS, the fraction of modified
hydroxyl groups per repeating unit) was determined by
the relative integration of the tyramine peaks (IT1,T2 in
Fig. 1) of the modified groups to methyl protons of the
internal standard (ICH3 in Fig. 1), according to Eq. 1,
adapted from another DS calculation as reported in sever-
al studies [26, 27]. The nHT1, T2, and nHCH3 correspond to
the number of tyramine protons and the methyl protons of
GG monomer, respectively. nOH corresponds to the num-











Horseradish peroxidase to induce tyramine-gellan gum
hydrogels formation
Horseradish peroxidase (HRP) solution (0.84 mg mL−1)
(Sigma-Aldrich, USA) and hydrogen peroxide solution
(H2O2) (0.36% (v/v)) (VWR, USA) were both prepared in
water. Tyramine-gellan gum solution of 1% (w/v) was used
for the hydrogel preparation. Tyramine-gellan gum hydrogels
were prepared by mixing of Ty-GG solution with different
amounts of HRP and H2O2 solutions (Table 1). Ty-GG hy-
drogel discs were prepared by adding 200 μL of the mixture
solutions in a polypropylene mold at 37 °C.
Water uptake and weight loss of the tyramine-gellan gum
hydrogels
Weight loss and water uptake of Ty-GG hydrogels were per-
formed. Hydrogels were soaked into a PBS solution at 37 °C,
for up to 21 days, in triplicate. Then, specimens were removed
after the different time points of immersion. The initial weight
(Wi) of each sample wasmeasured, and then Ty-GG hydrogels
were immersed in PBS solution. At each time point, the sam-
ples were removed and put in a filter paper to remove the
excess of the solution, and the wet weight (WW) was mea-
sured. The water uptake was determined as shown in Eq. 2.
Water uptake %ð Þ ¼ ww−wi
wi
 100 ð2Þ
The weight loss was quantified after the samples were dried
at 70 °C and until they reached constant weight (Wf), using Eq.
3.
Weight loss %ð Þ ¼ wi−w f
wi
 100 ð3Þ
Investigation of gelation time, injectability tests,
and rheological properties
The vial inversion test was routinely used to determine an
approximate gelation time. Thereby, after mixing Ty-GGwith
HRP and H2O2, the vials were placed in the water bath at 37
°C and then inverted to see how long it takes to turn to gel.
The injectability tests were also investigated by means of
injectability measurement equipment (PARALAB). The
injectability measurements were performed using a syringe
with a 27 G needle. The material was placed in the syringe
that was placed in the equipment, and then it applied a force
that extruded the sample from the syringe at a rate of 1 ml
min−1. The force needed for each hydrogel condition was
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recorded. Triplicates of each sample were performed, and wa-
ter was used as a control.
The mechanical properties of Ty-GG hydrogels were eval-
uated by using a rheometer (Kinexus pro+rheometer, software
rSpace, fromMalvern). The oscillatory experiments were per-
formed using a stainless-steel plate-plate measuring system.
This system is composed of an upper stainless-steel plate of
8 mm diameter, with a rough finish to prevent the sample from
slipping. Frequency sweep curves, also known as mechanical
spectra, were obtained from 0.01 to 1 Hz of frequency, at a
shear strain of 0.1% (from LVER determination) for 5 min at
37 °C. These curves were obtained in three independent tests,
with different samples of the same condition.
Drug release profile of the betamethasone-loaded
tyramine-gellan gum hydrogels
To assess the drug release system, one corticosteroid,
betamethasone, was incorporated in Ty-GG hydrogels. Ty-
Fig. 1 1H-NMR spectra (a) of
GG (i), tyramine (ii), and the
obtained Ty-GG (iii) in D2O at 50
°C. FTIR spectra (b) of GG (i),
tyramine (ii), and Ty-GG (iii)
Table 1 Ty-GG
conditions (C1, C2, and
C3) with different
amounts of HRP and
H2O2 solutions
Ty-GG HRP H2O2
C1 167 μL 16.6 μL 10.83 μL
C2 167 μL 18.3 μL 15 μL
C3 167 μL 20 uL 13.3 μL
Drug Deliv. and Transl. Res.
GG hydrogels loaded with betamethasone (Sigma-Aldrich,
USA) were prepared by mixing Ty-GG solution, with 5 mg
mL−1 of betamethasone in PBS, and the enzymatic
crosslinking was made by adding of HRP and H2O2.
Betamethasone release profile in Ty-GG 1% hydrogels was
evaluated immersing each hydrogel in PBS at 37 °C. After
each time point (3 h, 6 h, 24 h, 72 h, 168 h, 336 h and 504 h),
the supernatant was removed and kept at − 80 °C until the end
of the experiment. Three samples per condition were used at
each time point. To formulate the calibration curve,
betamethasone dilutions were prepared (from 0 to 5 mg
mL−1). The UV absorbance at 490 nm was read in a micro-
plate reader (EMax; Molecular Devices, Sunnyvale, CA,
USA) to measure the betamethasone release.
In vitro studies
Cell culture
Chondrogenic primary cells isolated from female New
Zealand White rabbits (Damul Sci., Korea) with 1 kg and 6
weeks were used. Dulbecco’s modified eagle medium
(DMEM/ F12) (Gibco, USA) was used in chondrogenic cells.
This culture medium was supplemented with 10% (v/v) fetal
bovine serum (Gibco, USA) and 1% (v/v) antibiotic-
antimycotic (Gibko/Thermo Fisher Scientific, South Korea)
under standard conditions (37 °C in a humidified atmosphere
containing 5% CO2). Human monocytic cell line (THP-1)
(SIGMA, USA) was expanded in RPMI 1640 Medium,
GlutaMAX™ Supplement, HEPES (Thermo Fisher
Scientific, USA), supplemented with 10% fetal bovine serum
and 1% (v/v) of penicillin and streptomycin, under standard
culture conditions (37 °C in a humidified atmosphere contain-
ing 5 vol% CO2).
Chondrogenic cell isolation
Chondrogenic primary cells were isolated from rabbit carti-
lage. The knees were initially removed from the rabbit, and the
samples were washed 3 times with PBS (1X) solution. The
cartilage was scraped carefully with the blade, and small frag-
ments were placed inside a conical tube with 1.5% (v/v) anti-
biotic-antimycotic. The sample was centrifuged at 300 G,
3 min and 4 °C. The supernatant was discarded and refilled
with an enzymatic cocktail (DMEM/F12 medium + collage-
nase A (Roche, USA). The solution was previously filter-
sterilized through a 0.2 μm filter. The sample was placed in
the CO2 incubator at 37 °C for 24 h. The next day, cells were
centrifuged at 300 G, for 3 min and at 4 °C. The supernatant
was removed, and the cells were plated on a cell culture dish,
with a complete medium and kept in the CO2 incubator at 37
°C until they reach the desired confluence.
Metabolic activity
The metabolic activity of chondrogenic primary cells was
assessed by MTT assay following the MEM extract test. The
MEM extract test protocol followed was established accord-
ing to the European and international standards.
The Ty-GG hydrogels (C1, C2, and C3 (previously
described)) were prepared with a thickness ranging from
0.5 to 1 mm, a minimum area of 60 cm2. The samples
were placed in a sterile tube with 10/20 mL of cell culture
medium, and they were kept in the water bath at 37 °C
and 60 rpm for 24 h. Parallel 200 μL cell suspension was
transferred into 96-well plates to obtain a cell density of
10,000 cells per cm2. After 24 h of incubation, the extrac-
tion fluid was passed through a 0.45 μm membrane filter,
and the medium of cells was removed and replaced with
the extraction fluid. Cells with DMEM-F12 medium were
used as control.
The cell cultures were evaluated by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, South
Korea) at 24, 48, and 72 h. At each time point, the DMEM/
F12 medium was replaced by culture medium containing
MTT assay in a 9:1 ratio and incubated for 3 h. When violet
crystals were formed, they were melted using dimethyl sulf-
oxide solution (DMSO). Then, 100 μL of solution from each
well was transferred to 96-well plates, and a microplate reader
(EMax; Molecular Devices, Sunnyvale, CA, USA) was used
at 570-nm optical density.
DNA quantification
The total amount of DNA was assessed using DNA quantifi-
cation kit (Quant-iT™ PicoGreen® dsDNA Assay Kit,
Invitrogen, USA), to evaluate the effect of Ty-GG hydrogels
in chondrogenic primary cells. The cells were seeded at a
density of 10,000 cells per cm2 and incubated with extraction
solution of Ty-GG hydrogels (C1, C2, and C3) for periods of
24, 48, and 72 h. After the incubation period of the cells, they
were washed with PBS solution and were lysed with water
pure water. The cell solution was placed into microtubes, in-
cubated for 1 h in a water bath at 37 °C, and then they are
stored at − 80 °C for further analysis. Cells cultured with
DMEM-F12 medium were used as a positive control.
Several solutions were prepared, with concentrations ranging
from 2 to 0 μL mL−1 to plot a DNA calibration curve. In each
well (of the 96-well opaque plate), 28.7 μL of each sample or
standard was mixed with 71.3 μL of PicoGreen solution and
100 μL 1X TE. Then, the plate was incubated in the dark for
10 min, the fluorescence was read using excitation of 480/20
nm and emission of 528/20 nm in a microplate reader,
and DNA concentration was determined from the standard
curve.
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Fluorescence microscopy
Chondrogenic primary cells were seeded using the same pro-
tocol and conditions described above. Then, cells were fixed
with 10% formalin (Sigma-Aldrich, USA) and stained with
Texas Red-X phalloidin (Sigma-Aldrich, USA) for actin fila-
ments of the cytoskeleton and 4,6-diamidino-2-phenylindole,
dilactate (DAPI blue, VWR International, USA) for nuclei. At
the end, cells were analyzed under the fluorescence micro-
scope (Axiolmager, Z1, Zeis Inc., Oberkochen, Germany).
Anti-inflammatory activity of betamethasone-loaded Ty-GG
hydrogels
The anti-inflammatory activity of betamethasone-loaded Ty-
GG hydrogels was investigated with a THP-1 cell line. For
this assay, the two concentrations that obtained the best results
in metabolic activity and cell proliferation were evaluated.
First, THP-1 cell line was seeded (1 × 106 cells per mL) and
differentiated into macrophage phenotype with 100 nM
phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich,
USA) for 1 day. The next day, the non-adhered cells were
removed, the medium replaced, and new RPMImediumwith-
out PMA was added, for 2 days. THP-1 cells were incubated
for 5 h with 100 ngmL−1 of lipopolysaccharide (LPS) (Sigma-
Aldrich, USA) in RPMI medium to enable the inflammatory
response. After incubation time, cells were cultured with two
concentrations of betamethasone-loaded Ty-GG hydrogels
(C1 and C2) for 7 days. Cells without treatment and differen-
tiated with PMA and without LPS stimulation were used as
control. At each time point (1 day, 3 days, and 7 days), the
solution was collected and kept at − 80 °C for further analysis.
Human TNF-alphaDuoSETELISA (R&DSystems, USA) kit
and DuoSet Ancillary Reagent Kit 2 (R&D Systems, USA),
for the optimum performance of the ELISA kit, were used to
assess the anti-inflammatory activity. The assay was per-
formed to evaluate the system effectiveness through cytokine
TNF-α. The TNF-α standards were prepared with concentra-
tions ranging from 1000 to 0 pg mL−1 to make a TNF-α
calibration curve. A microplate reader set (Synergy HT,
BIO-TEK) at 450 nm was used to determine the optical den-
sity of each well.
Statistical analysis
GraphPad Prism 8 version was used to conduct the statistical
analysis, where a Shapiro-Wilk normality test was formerly
performed to evaluate the data normality. Non-parametric
Kruskal-Wallis test was applied in all assays, except for
weight loss and MTT assay where one-way ANOVA was
used, since there was an absence of normality. Dunn’s multi-
ple comparison test was used to compare the mean rank of
each condition with the mean rank of every other condition in
non-parametric Kruskal-Wallis. Tukey’s multiple comparison
test was used to compare the mean of each condition with the
mean of every other condition in one-way ANOVA.
Statistical significances were determined as *p < 0.05, **p <
0.01, and ***p < 0.001. All tests were performed in triplicat-
ed, and results were presented with mean ± standard deviation.
Results and discussion
Physicochemical properties
Ty-GG hydrogels were obtained via enzymatic crosslinking
with HRP and H2O2 and encapsulated with betamethasone to
increase the specificity and safety in the treatment of chronic
inflammation of synovial joints in the patients suffering of
RA. Ty-GG was synthesized by amide bond formation be-
tween the amine group of tyramine and the carboxyl group
of GG. After the modification of GG with Ty, its efficacy was
evaluated by NMR and FTIR analysis. Figure 1 shows a rep-
resentative NMR spectrum (a) and FTIR spectra (b) of gellan
gum, tyramine, and Ty-GG.
From Fig. 1a, it is possible to see that Ty-modified gellan
gum (Ty-GG) (iii) showed additional peaks not appearing in
the unsubstituted GG (i). The tyramine spectrum (ii) showed
the distinctive signals for both pairs of aromatic ring protons
(β pair and λ pair between 7.4 and 7.1 ppm) and aliphatic side
chain protons between 3.4 and 3.1 ppm (α pair). These peaks
are seen in Ty-GG spectrum and confirm the presence of
tyramine on Ty-GG [28, 29].
The degree of substitution of GG with tyramine was calcu-
lated using Eq. 1. The obtained degree of substitution for Ty-
GG is (30.2 ± 1.3) %. This value of the degree of substitution
is higher when compared with other molecules modified with
tyramine [30, 31].
From Fig. 1b, the GG and Ty-GG spectra within the region
1800–1200 cm−1 also indicated the efficient modification of
tyramine-gellan gum. From the spectra analysis, it was possi-
ble to confirm the presence of the aromatic rings, due to the
appearance of a peak of C-C (in-ring) stretching vibrations at
1517 cm−1 and 1417 cm−1, only in the spectra of modified
gellan gum, which is in accordance with the spectra found in
the literature [25, 32].
It is known that ionic crosslinked hydrogels present weak
mechanical proprieties [33]. This limitation can be overcome
by modification of GG with tyramine, by enzymatic
crosslinking. Therefore, enzymatic but also physical and
chemical crosslinkings were combined to produce Ty-GG
hydrogels with tunable mechanical proprieties.
Ty-GG hydrogels were produced via enzymatic
crosslinking, with the enzyme HRP. Different conditions of
Ty-GG hydrogels were produced and assessed (C1, C2, and
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C3) regarding water absorption capacity and weight loss.
Figure 2 shows the water uptake and weight loss of C1, C2,
and C3 of Ty-GG hydrogels after soaking up to 504 h.
It was possible to verify that all conditions of Ty-GG
hydrogels showed negative values of water uptake. The swell-
ing ratios of gels ranged from (− 42.89 ± 6.25) %, (− 47.25 ±
1.47) %, (− 39.21 ± 1.53) % in the C1, C2, and C3, respec-
tively. Some studies [11, 26] demonstrated that the
crosslinking degree, the formation of ionic bonds, and hydro-
philicity of network of hydrogels influence the swelling. In the
swelling kinetics assays, the hydrogel behavior is powerfully
influenced by the presence of cations in the immersion solu-
tion [11]. These cations form ionic bonds that increase the
crosslinking degree and lower the water uptake ratio.
Interactions between the carboxylic group on GG and calcium
ions can reduce the hydrogen binding donors and receptors
free for interaction with water, thereby decreasing the quantity
of water related with the hydrogel network [34].
The results are in agreement with the previously mentioned
studies [26, 34, 35]; the Ty-GG hydrogels produced by enzy-
matic crosslinking, after immersion in PBS (ionic
crosslinking), did not present water absorption capability.
Thus, it is possible to consider this test as an indirect method
to assume a high crosslinking degree in the produced gels,
thus showing that the properties of GG improved after
modification.
The degradation profile of hydrogels in this study was ob-
tained by exposing the Ty-GG hydrogels in PBS at different
points (Fig. 2b). The weight loss results show that all concen-
trations had approximately the same degradation profile over
time. The weight loss ratio was (40.8 ± 4.1) %, (36.2 ± 0.7)
%, and (41.9 ± 1.6) %, for C1, C2, and C3, respectively. Ty-
GG hydrogels are relatively stable in PBS due to the ionic
crosslinking, being possible to observe a similar weight loss rate
over time. The osmotic forces influence this process, such as the
external ionic aqueous solution and the elastic force executed by
the crosslinked polymeric structure [36]. When the external so-
lution is ionically more concentrated than the hydrogels, the ions
can penetrate the hydrogels. Consequently, the hydrogel
crosslinking degree is stabilized and increased, being the water
molecule expulsion stimulated and consequently the weight loss
decreased. Furthermore, the ionic crosslink, when combined
with chemical crosslink mechanisms extend the rate of degrada-
tion, as reported by several studies [26, 35].
The gelation time is a crucial parameter for the formation of
hydrogels in situ and is widely connected with the
crosslinking rate of the HRP-catalyzed reaction [23]. The ge-
lation time was determined by the vial inversion test. After
adding Ty-GG with HRP and H2O2, the vials were placed at
37 °C in the water bath and then inverted. It was possible to
verify that all concentrations (C1, C2, and C3) had a gelation
time about 30 s.
Several studies reported that HRP catalyzes the
crosslinking reaction of polymer-phenol conjugates in the
presence of H2O2, resulting in hydrogels with tunable gelation
rate [20]. The HRP and H2O2 concentrations are essential
parameters to control the crosslinking rate of phenol-rich
polymers. The association between these parameters and ge-
lation time has beenwell-known. It has been described that the
gelation time reduced with rising HRP concentration [37, 38].
In order to use injectable hydrogels for bio-applications, a
suitable gelation time is desired. A short gelation time (10 s
to a few minutes) is essential for efficient local delivery of
drugs [31, 39]. While a quick gelling time is beneficial to
obtain high loading efficiency of drugs in hydrogels, in a real
clinical setting, rapid administration can be more challenging.
The use of appropriate syringes, with more than one channel,
in which the mixture is made while the injection is given,
would be the most appropriate form of administration.
Through the results obtained, it was possible to confirm that
the produced gels fulfill the necessary characteristics.
The injectability (formulation performance during injec-
tion, including pre-filled syringes) is a very important param-
eter to determine the force required to extrude the material
through a device [40]. The injectability analysis was per-
formed for the three conditions of hydrogels (C1, C2, and
C3), and water was used as control. The syringe was loaded
Fig. 2 Water uptake (a) and weight loss (b) of Ty-GG hydrogels after 24
h, 72 h, 168 h, 336 h, and 504 h of soaking. Significant differences ***p <
0.001, **p < 0.01, and *p < 0.05. Water uptake, significant differences
between (C2 vs C3) *p < 0.05 at time point 1 day and 3 days, non-
parametric Kruskal-Wallis test. Weight loss, significant differences be-
tween (C1 vs C2) **p < 0.01 at time point 3 days, one-way ANOVA
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with the Ty-GG solution, HRP, and H2O2 to form the
hydrogels, and the injection was performed using a rate of 1
mL min−1. The force needed for each injection was measured,
together with the control (water), and is presented in Fig. 3.
In Fig. 3, it was visible that the force needed to inject the
condition 1 (5.2 ± 0.3) N and condition 2 (4.9 ± 0.2) N is
greater than the force required to inject water (3.9 ± 0.1) N.
However, the force required to inject condition 3 (4 ± 0.1) N is
comparable with the force required to inject water. Initially, in
condition 1, there was a lower value in the injectability force,
with that force increasing around 23 s, possibly due to the
beginning of the crosslinking in the reaction, and then the
value remained constant until the end of the analysis. In con-
dition 2, the same profile of injectability as in condition 1 was
observed, although the values of the injectable force were
lower, and the increase of force occurred around 31 s. This
result may be due to condition 1 having a slightly higher
degree of crosslinking when compared with condition 2;
therefore, there is a slight difference in behavior. In condition
3, there was an injectability force value similar to the value
obtained with water. However, in condition 3, there was also
an increase in the injectable force around 31 s, which, like the
other conditions, maybe due to the beginning of the
crosslinking of the reaction. Taking this into account, condi-
tion 3 has presented an injectable force more similar to that
found in water, meaning that it can become easier and less
painful to inject into the patient. However, conditions 2 and 3,
despite having higher injectable force values, may have other
advantages as was verified in other characterization tests.
The mechanical properties of Ty-GG hydrogels were
assessed after enzymatic crosslinking via HRP and stabilized
at different time points in PBS. The hydrogels were evaluated
through oscillatory rheology experiment at 37 °C. The oscil-
latory shear flow has been extensively used to measure visco-
elastic properties of materials. The storage modulus, elastic
solid-like behavior, (G`), provides a small amplitude of oscil-
latory shear and lossmodulus, and the viscous response, (G``),
assesses stress amplitude and the time lag between the stress
and strain. The phase angle (δ, 0 ≤ δ ≤ 90°) is a representative
physical property that estimates the viscoelasticity of a mate-
rial. G`, G``, and δ are determined by a single function of the
frequency (f). These materials are often called linear visco-
elastic properties. A general form of the shear stress subjected
to oscillatory shear (λ = λ0sinωt) [41]. Figure 4 shows the
mechanical spectra of Ty-GG hydrogels (C1, C2, and C3),
after different time points.
The spectrum of mechanical proprieties of Ty-GG
hydrogels showed that at 24 h and 72 h, all conditions of
Ty-GG hydrogels demonstrated a G`` > G` and consequently
presented a high phase angle, that is, a viscous component
higher than the solid. In the following time points, 168 h,
336 h, and 504 h, it was possible to observe that the phase
angle decreased, G` > G``, so the elastic component is higher
than the viscous component, showing that the material has a
viscoelastic behavior, with superior elastic character [41, 42].
The Ty-GG hydrogels are intended to be injected in the syno-
vial cavity filled with synovial fluid. This fluid has highly
viscous (G`` > G`) properties, and the hydrogels obtained
showed viscoelastic behavior with high viscosity after forma-
tion, similar to the synovial liquid. Thus, Ty-GG hydrogels
achieved the desired mechanical properties [43, 44].
Viscoelastic materials, such as the proposed Ty-GG
hydrogels, can be injected directly into the knee joint of pa-
tients with RA and, in addition to function as a drug carrier,
surrounding the deficient cartilage joints and acting as a lubri-
cant and shock absorber [45], as well as reducing pain and
slowing down the disease progress.
Controlled drug delivery is revealing great importance over
conventional drug delivery methods. In traditional drug ad-
ministration, drug concentration in the blood rises instantly
after the drug is taken and then decreases over time. Plasma
drug concentration is a vital parameter for any drug since there
is an optimum concentration above which it is toxic and below
which it is not effective. The conventional drugs are also very
limited concerning their short half-lives and their stability only
under physiological conditions. Therefore, drug delivery at a
constant rate is generally better compared with the traditional
methods of drug administration [46–48].
Betamethasone suspensions were approved for intra-
articular injection to provide adjuvant therapy in rheumatoid
arthritis. Normal intra-articular doses of betamethasone sus-
pensions differ with the size of the joint, from 1.5 to 12 mg
[49]. In this work, 5 mg mL−1 of betamethasone was used
because it was the average value found in the literature to have
a therapeutic effect. The betamethasone has a short half-life
about 36–54 h [50], which means that the drug must be
injected more frequently to have the desired therapeutic effect.
It was possible to verify that the Ty-GG hydrogels allowed a
controlled release profile of betamethasone over 21 days, not
reaching the maximum of release in any of the concentrations,
Fig. 3 Injectability test of Ty-GG hydrogels, C1, C2, and C3, and water
(control). Significant differences ***p < 0.001 (water vs C1) and (water
vs C2), non-parametric Kruskal-Wallis test
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C1 released (64 ± 1.5) % of the drug, C2 released (51 ± 0.8)%,
and C3 released approximately (82 ± 0.05)% (Fig. 5). Intra-
articular corticosteroid therapy has been used for the treatment
of RA. Corticosteroid therapy is effective at temporarily alle-
viating joint symptoms associated with inflammatory disor-
ders. However, long-term adverse effects of corticosteroids
on chondrocyte of the articular cartilage are a concern. Thus,
the number of injections is usually restricted [51, 52]. The use
of Ty-GG hydrogels loaded with betamethasone allows the
drug to be administered less frequently, providing lower and
continuous dosages of the drug, thus decreasing the levels of
toxicity. In addition, constant injections can become painful
and uncomfortable for patients. Thus, the use of Ty-GG
hydrogels to betamethasone release can improve the failures
of the traditional models, allowing a better quality of patient’s
life during the treatment period.
In vitro studies
Cell viability and proliferation of Ty-GG hydrogels were
assessed in chondrogenic primary cells, and therapeutic effi-
cacy was evaluated using the THP-1 cell line.
MTT assay was made to investigate the influence of Ty-
GG hydrogels. Thus, the metabolic activity of cells up to 72 h
of culturing (Fig. 6a) was evaluated. DNA quantification was
also performed to assess cell proliferation (Fig. 6b).
From day 1 to day 3, all cells with different conditions of
Ty-GG hydrogels have shown an increase of metabolic activ-
ity, not presenting significant differences between them.
However, on day 2, cells with C3 demonstrated significant
differences as compared with control (*p < 0.05).
In parallel, DNA quantification was performed to assess
cell proliferation for 72 h. It was observed that there was a
decrease in the first time point in C2 and C3 samples, although
there were no significant differences. At the following time
points, there was an increase in cell proliferation in all condi-
tions, and no significant differences were found between
conditions.
Fig. 4 Mechanical spectra of Ty-
GG hydrogels: C1 (a), C2 (b),
and C3 (c) at different time points
(24 h, 72 h, 168 h, 336 h, and 504
h). Significant differences ***p <
0.001, **p < 0.01, and *p < 0.05,
non-parametric Kruskal-Wallis
test
Fig. 5 Drug release profile of Ty-GG hydrogels (C1, C2, and C3) with
encapsulated betamethasone for 3 h, 6 h, 24 h, 72 h, 168 h, 336 h, and 504
h. Significant differences ***p < 0.001, **p < 0.01, and *p < 0.05, by
non-parametric Kruskal-Wallis test. At time point 1 day, significant dif-
ferences between (C2 vs C3) *p < 0.05, at time point 3 days (C2 vsC3) *p
< 0.05, at time point 14 days (C1 vs C2) *p < 0.05
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These results are in line with those found in the literature,
i.e., modified GG is not cytotoxic over different cell types
[53–55].
Qualitative analysis of the morphology of chondrogenic
primary cells in contact with Ty-GG hydrogel extracts was
obtained by fluorescence microscopy (Fig. 7).
Chondrogenic primary cells were cultured with different
conditions of extraction fluid of Ty-GG hydrogels. It was
possible to verify that none of the conditions produced affect-
ed the typical morphology of the chondrogenic cells (marked
by DAPI and phalloidin), suggesting healthy proliferation and
survival.
Then, the rates of the pro-inflammatory tumor necrosis
factor alfa (TNF-α), present in the medium after being in
contact with Ty-GG hydrogels, were assessed. This cytokine
is found in large quantities in patients with RA and has been
studied with a therapeutic target. THP-1 cell line was differ-
entiated with PMA and stimulated with LPS to assess the
capaci ty of Ty-GG hydrogels encapsulated with
betamethasone to decrease the levels of TNF-α present in
the medium. Only C1 and C2 were analyzed regarding the
neutralizing capacity since these were the best conditions in
previous metabolic activity and cell proliferation. After the
inflammation is manifested, 7 conditions were established to
test, cells stimulated with LPS, without treatment,
betamethasone alone, Ty-GG hydrogels (C1 and C2) without
betamethasone encapsulated, and Ty-GG hydrogels (C1 and
C2) encapsulated with betamethasone. Cells differentiated
with PMA but without LPS stimulation were used as control.
Figure 8 shows the graphs of C1 (a) and C2 (b) separately,
regarding the amount of TNF-α present in RPMI medium for
1 day, 3 days, and 7 days of culturing.
The results showed that cells stimulated with LPS but with-
out treatment demonstrated high levels of free TNF-α in the
RPMI medium, compared with the other conditions.
Furthermore, it was possible to verify a higher neutralization
of TNF-α in THP-1 cells treated with Ty-GG hydrogels en-
capsulated with betamethasone (C1 and C2) than with Ty-GG
(C1 and C2) and betamethasone alone (C1 and C2).
Significant differences were found between cells stimulated
with LPS without treatment and cells that were treated Ty-GG
hydrogels encapsulated with betamethasone (*p < 0.05). This
significant difference was more evident in C1 than C2, at the
first time point.
The higher ability to neutralize the TNF-α becomes more
noticeable on the 7th day, which may be because hydrogels
are degrading, so a higher amount of drug is released.
Ty-GG hydrogels loaded with betamethasone can bring
more advantages in the treatment of the inflammatory envi-
ronment than the drug alone. This approach may allow a
prolonged action, due to the controlled rate of drug release
over time, and treat inflammation more effectively in patients
with RA. Furthermore, as mentioned earlier, it can reduce
frequent administration of the drug to patients, decreasing
the level of toxicity caused by recurrent administrations.
The data is in agreement with the previously reported
literature [56–58] where it was shown a great potential of
GG for distinct applications, such as mucoadhesive, transder-
mal and colon targeted controlled drug release systems.
Conclusion
This study developed tyramine-substituted gellan gum
hydrogels via enzymatic and physical crosslinking, where
betamethasone encapsulated can increase the specificity and
safety in the treatment of patients with RA. The gellan gum
was effectively modified with tyramine, presenting a substitu-
tion degree of about 30%. Tyramine-substituted gellan gum
hydrogels showed rapid gelation time and demonstrated a
good strength and resistance, ideal to be applied in the intra-
Fig. 6 MTT assay (a) and DNA quantification (b) of chondrogenic
primary cells with control (cells with DMEM-12 medium) and different
conditions (C1, C2, and C3) of Ty-GG hydrogels, after 24 h, 48 h, and
72 h of culturing. Significant differences ***p < 0.001, **p < 0.01, and
*p < 0.05. Ordinary one-way ANOVA (MTT assay) and non-parametric
Kruskal-Wallis test (DNA quantification)
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articular cavity. The tyramine-substituted gellan gum
hydrogels presented low water absorption capacity, a constant
weight loss profile, and a controlled betamethasone release
profile over time. Thus, it can be considered that the properties
of gellan gumwere improved after modification. Furthermore,
the tyramine-substituted gellan gum hydrogels did not show to
cause toxic effects onmetabolic activity, morphology, and cell
proliferation, and tyramine-substituted gellan gum hydrogels
with betamethasone encapsulated demonstrated more effec-
tive therapeutic efficacy over time than betamethasone alone.
Therefore, tyramine-substituted gellan gum hydrogel has ex-
cellent potential to be used as a drug delivery system for the
treatment of rheumatoid arthritis.
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